

# Technical Notes

## Lifetime Risk

DevCan software was used to compute lifetime risk.

[http://seer.cancer.gov/csr/1975\\_2012/results\\_merged/topic\\_lifetime\\_risk\\_diagnosis.pdf](http://seer.cancer.gov/csr/1975_2012/results_merged/topic_lifetime_risk_diagnosis.pdf)

DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.2;  
Statistical Research and Applications Branch, National Cancer Institute, 2005.

<http://srab.cancer.gov/devcan>

The data presented in this fact sheet were modeled after methodologies from The SEER Cancer Statistics Review, 1975-2012, Lifetime Risk. Lifetime risk estimates for this report were calculated using a follow-back year of 1995 and the most recent three years of incidence and mortality data at the time (2010-2012) which is consistent with the National Cancer Institute's (NCI), SEER Cancer Statistics Review (CSR) 1975-2012. Since lifetime risk estimates calculate risk based on the first primary cancer only and the follow back year sets the point in time that multiple primaries are first counted, the earlier the follow-back year is set, the higher the number of cases during the analysis period will be excluded. For example, although this analysis selects cases diagnosed from 2010-2012, if a patient was diagnosed with an earlier primary cancer from 1995-2009, that case will be excluded from the analysis. If the same analysis set the follow back year to 2000, a case diagnosed from 2010-2012 with an earlier primary in 1995 would not be excluded. For these reasons, follow back year will greatly influence the risk estimate. For this analysis, the SEER 13 file with follow back to 1995 was used as opposed to the SEER 18 file which limits public users to a follow back year of 2000. Slight differences in lifetime risk estimates may be seen between this report and the CSR due to the data sources. Questions related to this procedures may be addressed to [pamela.agovino@doh.state.nj.us](mailto:pamela.agovino@doh.state.nj.us).

A description of how DevCan software calculates the lifetime risk of developing cancer can be located at

<http://surveillance.cancer.gov/devcan/>

All cancer statistics presented in this fact sheet are invasive with the exception of bladder cancer which includes both *in situ* and invasive cancers. All invasive cancer excludes basal cell and squamous cell skin cancer.

Source :

Incidence - New Jersey State Cancer Registry, Jan 2015 Analytic File (1979-2012), using National Cancer Institute SEER\*Stat software (www.seer.cancer.gov/seerstat) version 8.2.1

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\*Stat Database: Incidence - SEER 13 Regs Research Data, Nov 2014 Sub (1992-2012) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.

### New Jersey Age-Adjusted Cancer Death Rates by Sex, 2010-2012

	Male & female			Male			Female		
	Rate	Lower CI	Upper CI	Rate	Lower CI	Upper CI	Rate	Lower CI	Upper CI
All Causes of Death	682.0	679.1	685.0	817.6	812.5	822.7	579.4	575.8	582.9
All Malignant Cancers	164.8	163.4	166.3	196.7	194.2	199.2	144.2	142.4	146.0

### US Age-Adjusted Cancer Death Rates by Sex, 2010-2012

	Male & female			Male			Female		
	Rate	Lower CI	Upper CI	Rate	Lower CI	Upper CI	Rate	Lower CI	Upper CI
All Causes of Death	736.6	736.1	737.2	873.7	872.8	874.6	626.0	625.4	626.7
All Malignant Cancers	168.9	168.7	169.2	204.5	204.0	204.9	143.7	143.4	144.0

Underlying mortality data provided by NCHS ([www.cdc.gov/nchs](http://www.cdc.gov/nchs)).

Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard;

Confidence intervals (Tiwari model) are 95% for rates.

All malignant cancer excludes basal cell and squamous cell skin cancer and *in situ* cancers except urinary bladder.

Authored by

Pamela K. Agovino MPH, Raj P. Gona, MPH, Stasia Burger, MS CTR, Lisa Paddock, PhD, MPH, Antoinette Stroup, PhD,  
Karen Pawlish, ScD, MPH, Katharine McGreevy, MPA., PhD and Barbara Goun, PhD

Cancer Epidemiology Services

<http://www.state.nj.us/health/ces/index.shtml>

Environmental and Occupational Health Surveillance Program - Cancer Surveillance Unit

<http://www.nj.gov/health/ces/public/surveillance.shtml>

New Jersey Department of Health, Trenton, NJ 08625-0369

January 2016